Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label trial of epcoritamab versus investigator's choice chemotherapy in relapsed or refractory diffuse large B-cell lymphoma
NL-OMON54027Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Jan 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) and 1 more (2 arms), sponsored by Genmab. Primary endpoint: Overall survival. Started Jan 2022; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH)
Beyond the preview
Go deeper on NL-OMON54027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54027.